Table 2.

Annual mean number of asthma-related events before and after treatment with omalizumab or mepolizumab

	Omalizumab (n = 25)			Mepolizumab (n = 24)
	Pre-administration	Post-administration	p value	Pre-administration	Post-administration	p value
Exacerbations	4.08 (± 3.58)	2.68 (± 3.76)	0.054	1.42 (± 1.72)	0.54 (± 1.02)	0.005
ER visits	1.04 (± 1.43)	0.40 (± 1.08)	0.005	0.33 (± 0.56)	0.12 (± 0.34)	0.109
Hospital admissions	0.56 (± 0.92)	0.24 (± 0.83)	0.098	0.17 (± 0.38)	0.04 (± 0.20)	0.233

p values were calculated using the Wilcoxon signed-rank test for within-group comparisons

The median treatment duration was 365 days in both groups

ER: emergency room